Evolving landscape of potassium-competitive acid blockers: toward disease-specific use beyond acid suppression
Abstract
Potassium-competitive acid blockers (P-CABs) represent a major advancement in acid suppression by achieving rapid and sustained inhibition of gastric acid secretion. However, stronger acid suppression does not necessarily lead to better clinical outcomes. The clinical benefits of P-CABs vary according to the disease. In gastroesophageal reflux disease, P-CABs achieve healing rates for erosive esophagitis that are comparable to those of proton pump inhibitors (PPIs), with possible advantages in severe cases; however, consistent superiority in symptom control is lacking. The evidence for functional dyspepsia also remains insufficient. By contrast, in Helicobacter pylori eradication, P-CAB-based regimens have demonstrated clear advantages, particularly in the presence of antibiotic resistance. In peptic ulcer disease, the efficacy of P-CABs is comparable to that of PPIs. Long-term safety, including the effects of sustained hypergastrinemia, remains uncertain. Furthermore, symptom improvement and mucosal healing are not always concordant, thus highlighting the need to define therapeutic goals. Therefore, P-CABs should be used selectively on the basis of disease-specific requirements rather than pharmacological potency alone. An individualized approach is essential to optimize outcomes and avoid the unnecessary escalation of acid-suppressive therapy.
Read the paper
Related studies
- Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
- Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
- Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study
- Ethnic and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.